PHAT

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Phathom Pharmaceuticals Inc

NASDAQ | PHAT

13.49

USD

$0.00

(

0.00%

)

At Close (As of Nov 4, 2025)

$976.73M

Market Cap

-

P/E Ratio

-3.76

EPS

$19.05

52 Week High

$2.21

52 Week Low

HEALTHCARE

Sector

PHAT Chart

Recent Chart
Price Action

PHAT Technicals

Tags:

PHAT Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $47M
Total Revenue $55M
Cost Of Revenue $8M
Costof Goods And Services Sold $8M
Operating Income -$277M
Selling General And Administrative $291M
Research And Development $34M
Operating Expenses $325M
Investment Income Net -
Net Interest Income -$57M
Interest Income $15M
Interest Expense $72M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $795K
Income Before Tax -$334M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$334M
Comprehensive Income Net Of Tax -
Ebit -$262M
Ebitda -$262M
Net Income -$334M

Revenue & Profitability

Earnings Performance

PHAT Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $378M
Total Current Assets $360M
Cash And Cash Equivalents At Carrying Value $297M
Cash And Short Term Investments $297M
Inventory $3.2M
Current Net Receivables $39M
Total Non Current Assets $18M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $21M
Other Non Current Assets -
Total Liabilities $632M
Total Current Liabilities $86M
Current Accounts Payable $11M
Deferred Revenue -
Current Debt -
Short Term Debt $20M
Total Non Current Liabilities $546M
Capital Lease Obligations $501K
Long Term Debt $201M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $555M
Other Current Liabilities $55M
Other Non Current Liabilities $345M
Total Shareholder Equity -$254M
Treasury Stock -
Retained Earnings -$1.3B
Common Stock $6K
Common Stock Shares Outstanding $63M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$267M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $795K
Capital Expenditures $135K
Change In Receivables -
Change In Inventory -$6.1M
Profit Loss -
Cashflow From Investment -$135K
Cashflow From Financing $183M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$334M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $47M
Total Revenue $55M
Cost Of Revenue $8M
Costof Goods And Services Sold $8M
Operating Income -$277M
Selling General And Administrative $291M
Research And Development $34M
Operating Expenses $325M
Investment Income Net -
Net Interest Income -$57M
Interest Income $15M
Interest Expense $72M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $795K
Income Before Tax -$334M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$334M
Comprehensive Income Net Of Tax -
Ebit -$262M
Ebitda -$262M
Net Income -$334M

PHAT News

PHAT Profile

Phathom Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Florham Park, New Jersey, focusing on the development and commercialization of innovative therapies for gastrointestinal disorders. With a strong commitment to addressing unmet medical needs, Phathom is advancing a promising pipeline that includes novel treatment options, aiming to transform patient care in this critical therapeutic area. The company’s strategic emphasis on clinical development and potential product launches positions it favorably for growth and long-term value creation for investors.

PTLE
+51.53%
$0.28
MSPR
+27.56%
$0.66
SCNX
+15.35%
$0.81
NVDA
-3.95%
$198.69
BYND
-4.31%
$1.33
ORIS
-0.12%
$0.16
PFE
-1.45%
$24.30
VHAI
0.00%
$0.00
HTZ
+36.23%
$6.73
PLTR
-7.93%
$190.74
ASST
-1.57%
$1.25
GRAB
-4.69%
$5.78
INTC
-6.25%
$37.03
PLUG
-8.36%
$2.52
ONDS
-3.08%
$5.96
CHR
+8.10%
$0.13
DNN
-6.16%
$2.74
WTO
-6.22%
$0.04
TSLA
-5.14%
$444.26
CAPT
+31.77%
$0.66
KVUE
-1.05%
$15.97
NFE
+14.40%
$1.35
BITF
-6.56%
$3.84
YDKG
-3.39%
$0.05
EPWK
+3.60%
$0.07
T
-0.36%
$24.44
ETHD
+20.91%
$5.26
F
-1.69%
$12.79
ACHR
-8.25%
$9.56
SOFI
-4.11%
$29.37
AXDX
-61.36%
$0.03
CIFR
-1.09%
$22.51
GPUS
-7.02%
$0.34
HIMS
-3.60%
$42.79
CMBM
+58.82%
$3.24
BTBT
-7.01%
$3.18
BURU
-7.90%
$0.28
AAL
-5.17%
$12.65
NCLH
-15.28%
$18.79
AMD
-3.69%
$250.05
RGTI
-10.07%
$35.18
BTG
-5.88%
$4.00
RIVN
-5.23%
$12.50
CAN
-14.61%
$1.11
AMZN
-1.84%
$249.32
VALE
-2.13%
$11.94
ADAP
-15.14%
$0.05
MARA
-6.68%
$16.62
AAPL
+0.36%
$270.04
UBER
-5.06%
$94.67
TLRY
-5.34%
$1.24
BAC
-0.03%
$53.54
PLTZ
+16.06%
$6.07
SOUN
-11.57%
$15.13
BMNR
-7.93%
$39.46
IREN
-1.65%
$66.63
NOK
-4.75%
$6.81
SNAP
-4.47%
$7.47
WULF
-6.77%
$15.01
VSEE
+3.03%
$1.02
RXRX
-8.08%
$5.00
NIO
-3.50%
$7.16
RUBI
-11.62%
$0.60
WBD
+1.39%
$22.60
NGD
-8.79%
$6.64
CCL
-9.05%
$26.11
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
ADD
-25.47%
$0.05
NVTS
-14.61%
$10.46
RIG
-1.51%
$3.90
QBTS
-10.12%
$29.74
PLTD
+7.99%
$6.35
SRM
+53.27%
$10.30
CMG
+0.72%
$31.74
SMCI
-6.60%
$47.40
VZ
-0.38%
$39.32
DVLT
-3.26%
$1.78
LUMN
-10.90%
$10.54
HPE
-3.83%
$23.56
AMCR
+0.12%
$7.87
KDLY
-11.88%
$0.78
CDE
-8.71%
$13.82
NAKA
-11.88%
$0.78
CLF
-10.02%
$10.68
APLD
-5.50%
$31.06
GOOGL
-2.17%
$277.54
WLGS
-5.57%
$0.04
UUUU
-4.43%
$17.01
CLSK
-6.88%
$16.22
AGNC
+1.29%
$10.18
NVO
-1.75%
$48.25
RR
-8.78%
$4.05
IONZ
+17.01%
$4.47
CGC
-5.83%
$1.12
DENN
+50.36%
$6.18
CTRA
+5.98%
$25.85
FUBO
+6.35%
$3.68
ETWO
0.00%
$3.30
META
-1.62%
$627.32
PTLE
+51.53%
$0.28
MSPR
+27.56%
$0.66
SCNX
+15.35%
$0.81
NVDA
-3.95%
$198.69
BYND
-4.31%
$1.33
ORIS
-0.12%
$0.16
PFE
-1.45%
$24.30
VHAI
0.00%
$0.00
HTZ
+36.23%
$6.73
PLTR
-7.93%
$190.74
ASST
-1.57%
$1.25
GRAB
-4.69%
$5.78
INTC
-6.25%
$37.03
PLUG
-8.36%
$2.52
ONDS
-3.08%
$5.96
CHR
+8.10%
$0.13
DNN
-6.16%
$2.74
WTO
-6.22%
$0.04
TSLA
-5.14%
$444.26
CAPT
+31.77%
$0.66
KVUE
-1.05%
$15.97
NFE
+14.40%
$1.35
BITF
-6.56%
$3.84
YDKG
-3.39%
$0.05
EPWK
+3.60%
$0.07
T
-0.36%
$24.44
ETHD
+20.91%
$5.26
F
-1.69%
$12.79
ACHR
-8.25%
$9.56
SOFI
-4.11%
$29.37
AXDX
-61.36%
$0.03
CIFR
-1.09%
$22.51
GPUS
-7.02%
$0.34
HIMS
-3.60%
$42.79
CMBM
+58.82%
$3.24
BTBT
-7.01%
$3.18
BURU
-7.90%
$0.28
AAL
-5.17%
$12.65
NCLH
-15.28%
$18.79
AMD
-3.69%
$250.05
RGTI
-10.07%
$35.18
BTG
-5.88%
$4.00
RIVN
-5.23%
$12.50
CAN
-14.61%
$1.11
AMZN
-1.84%
$249.32
VALE
-2.13%
$11.94
ADAP
-15.14%
$0.05
MARA
-6.68%
$16.62
AAPL
+0.36%
$270.04
UBER
-5.06%
$94.67
TLRY
-5.34%
$1.24
BAC
-0.03%
$53.54
PLTZ
+16.06%
$6.07
SOUN
-11.57%
$15.13
BMNR
-7.93%
$39.46
IREN
-1.65%
$66.63
NOK
-4.75%
$6.81
SNAP
-4.47%
$7.47
WULF
-6.77%
$15.01
VSEE
+3.03%
$1.02
RXRX
-8.08%
$5.00
NIO
-3.50%
$7.16
RUBI
-11.62%
$0.60
WBD
+1.39%
$22.60
NGD
-8.79%
$6.64
CCL
-9.05%
$26.11
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
ADD
-25.47%
$0.05
NVTS
-14.61%
$10.46
RIG
-1.51%
$3.90
QBTS
-10.12%
$29.74
PLTD
+7.99%
$6.35
SRM
+53.27%
$10.30
CMG
+0.72%
$31.74
SMCI
-6.60%
$47.40
VZ
-0.38%
$39.32
DVLT
-3.26%
$1.78
LUMN
-10.90%
$10.54
HPE
-3.83%
$23.56
AMCR
+0.12%
$7.87
KDLY
-11.88%
$0.78
CDE
-8.71%
$13.82
NAKA
-11.88%
$0.78
CLF
-10.02%
$10.68
APLD
-5.50%
$31.06
GOOGL
-2.17%
$277.54
WLGS
-5.57%
$0.04
UUUU
-4.43%
$17.01
CLSK
-6.88%
$16.22
AGNC
+1.29%
$10.18
NVO
-1.75%
$48.25
RR
-8.78%
$4.05
IONZ
+17.01%
$4.47
CGC
-5.83%
$1.12
DENN
+50.36%
$6.18
CTRA
+5.98%
$25.85
FUBO
+6.35%
$3.68
ETWO
0.00%
$3.30
META
-1.62%
$627.32
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.